drugset / Trial / NCT03631862
Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Apatinib Combined With CHOP Regimen(cyclophosphamide, vincristine, epirubicin, prednisone in the treatment of newly diagnosed peripheral T-cell lymphoma.
Timeline
- Start
- 2018-09-01
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |
| Background | Cyclophosphamide | Other / unclassified | 750 mg | Intravenous |
| Background | Epirubicin | Small molecule | 60 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | 60 mg/m2 | Oral |
| Background | Vindesine | Small molecule | 1.4 g | Intravenous |